Physiology and treatment of hypertension

Thalgahagoda, Shenal; Shenoy, Mohan

doi:10.1016/j.paed.2012.08.003

Cited by 2 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half-normal probability plots for the analyzed responses were built (data not shown) allowing us to reach an analogous conclusion to that obtained from the consideration of the values collected in Table II. Since the factor BATN concentration^did not affect any response, for the optimization procedure, its concentration was fixed at 2 mg/mL which covers the daily therapeutic concentration in pediatrics (0.8 to 2 mg/kg/day) (32,33). Likewise, the factor BB^did not affect any response (Table II).…”

Section: Screening Phasementioning

confidence: 99%

First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation

et al. 2018

View full text Add to dashboard Cite

Liquid formulations can be used in children of different ages by varying the volume of the administered dose in order to ensure an exact dosage. The aim of this work was to develop and to optimize a safe liquid atenolol formulation and to carry out the corresponding chemical and microbiological stability studies. A Plackett-Burman design was used to determine the factors that could be critical in the development of the formulations, and a central composite design was used to determine the optimal working conditions. As a result of these analyses, three formulations were selected and their stability studied in three storage conditions, 4, 25, and 40°C. After 6 months of stability testing, the optimal systems showed no pH change or atenolol loss; however, only glycerin-based formulations showed no microbial development. These systems, employing excipients in a range that the EMA has recommended, showed chemical and microbiological stability for at least 6 months even at the worst storage conditions.

show abstract

Section: Screening Phasementioning

confidence: 99%

First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…High blood pressure is the result of elevation in either cardiac output or peripheral vascular resistance, or both. While, the cardiac output is determined by stroke volume and heart rate, the peripheral resistance is controlled by smooth muscle cells (SMCs) from small arteries and arterioles [3] (Fig. 1).…”

Section: Endothelial Dysfunction and Hypertensionmentioning

confidence: 99%

“…These lead to augmented cardiac contractility and hence amplified cardiac output and peripheral vascular resistance, in this way increasing blood pressure. An increase in blood pressure causes enhanced vagal tone, leading to bradycardia and vasodilatation [3].…”

Section: Endothelial Dysfunction and Hypertensionmentioning

confidence: 99%

“…Furthermore, the endothelial dysfunction and chronic hyperparathyroidism that enhance the sensitivity to calcium and catecholamines participate to hypertension observed in CKD. In addition to mentioned factors, hypertension is associated with endocrinopathies like hyperthyroidism, hyperparathyroidism, C u s h i n g s y n d r o m e , C o n n s y n d r o m e , a n d phaeochromocytoma [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of MicroRNA in Endothelial Dysfunction and Hypertension

2016

View full text Add to dashboard Cite

Herein we summarize the present understanding of mechanisms underlying hypertension and its associated endothelial dysfunction as well as the miRNA role in endothelial cells with accent on the modulation of renin-angiotensin-aldosterone-system, nitric oxide, oxidative stress and on the control of vascular inflammation and angiogenesis in relation to endothelial dysfunction in hypertension. In particular, latest insights in the identification of endothelial-specific microRNAs and their targets are added to the understanding of miRNA significance in hypertension. This comprehensive knowledge of the role of miRNAs in endothelial dysfunction and hypertension and of molecular mechanisms proposed for miRNA actions may offer novel diagnostic biomarkers and therapeutic targets for controlling hypertension-associated endothelial dysfunction and other cardiovascular complications.

show abstract

Physiology and treatment of hypertension

Cited by 2 publications

References 10 publications

First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation

First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation

Role of MicroRNA in Endothelial Dysfunction and Hypertension

Contact Info

Product

Resources

About